Singapore markets closed

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.7950-0.2550 (-5.05%)
At close: 04:00PM EST
4.8000 +0.01 (+0.10%)
After hours: 07:59PM EST

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500

Full-time employees28

Key executives

NameTitlePayExercisedYear born
Mr. Cezar Andrei Floroiu M.B.A.CEO, Pres, Principal Financial Officer & Director538.15kN/A1973
Ms. Margaret A. EcherdSr. VP & Principal Accounting Officer523.07kN/A1959
Dr. Sean N. TuckerSr. VP & Chief Scientific Officer530.72kN/A1968
Ms. Shaily Jaini GargSr. VP of Clinical Devel. & Project ManagementN/AN/AN/A
Mr. Brant BiehnSr. VP of Bus. OperationsN/AN/AN/A
Dr. Richard M. SchwartzSr. VP of Technical OperationsN/AN/AN/A
Dr. Rajesh Kapoor Ph.D.Sr. VP of QualityN/AN/AN/A
Dr. James F. Cummings M.D.Chief Medical OfficerN/AN/AN/A
Mr. John M. Harland M.B.A., CPAConsultantN/AN/A1952
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.

Corporate governance

Vaxart, Inc.’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.